Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET

Company Participants

Carrie Mendivil - Investor Relations

Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director

Anna Mowry - Chief Financial Officer

Parag Mallick - Co-Founder, Chief Scientist & Director

Conference Call Participants

Yuko Oku - Morgan Stanley

Daniel Brennan - Cowen

Matt Sykes - Goldman Sachs

Operator

Good morning and thank you for standing by. Welcome to the Nautilus First Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would not like to hand the conference over to your speaker today, Carrie Mendivil, Investor Relations. Please go ahead.

Carrie Mendivil

Thank you. Earlier today, Nautilus released financial results for the quarter ended March 31, 2023. If you haven't received this news release or if you'd like to be added to the Company's distribution list, please send an e-mail to investorrelations@nautilus.bio. Joining me today from Nautilus are: Sujal Patel, Co-Founder and CEO; and Anna Mowry, Chief Financial Officer. Nautilus Co-Founder and Chief Scientist, Parag Mallick, will be joining us for Q&A.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled "Forward-Looking Statements" in the press release of Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product -- pipeline projections or forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, May 2, 2023.

With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks, Carrie. Good morning and thank you to everyone for joining us today. On this call, we'll share our results for the first quarter and provide an update on recent activities. Since our call in February, we've made steady progress towards many of our key scientific and engineering objectives. That progress is the result of the outstanding work being done by our talented and dedicated teams in San Carlos, Seattle and San Diego. Every member of the Nautilus team understands that our long-term goal is to provide ubiquitous access to the proteome to every lab, researcher, and clinician around the world. We continue to see this as our long-term purpose, while recognizing the many intermediate benefits that will accrue to biological research and healthcare as we move towards that ultimate goal.